Beam Therapeutics (BEAM)’ treatment of alpha-1 antitrypsin deficiency was granted FDA orphan designation status, according to a post to the agency’s website.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics announces FDA grants RMAT designation to BEAM-302
- Beam Therapeutics: Promising Gene Editing Advancements and Strategic Execution Reinforce Buy Rating
- Beam Therapeutics: Promising Pipeline and Financial Stability Justify Buy Rating
- Beam Therapeutics: Promising Advancements in Base Editing and Strong Financial Position Support Buy Rating
- Beam Therapeutics price target lowered to $55 from $78 at Guggenheim
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue